Vasopressin receptors are a family of tissue-specific G protein-coupled receptors, which classified into V1, V2 and V3 subtypes. These three subtypes differ in localization, function and signal transduction mechanisms. Although all three of these proteins are G-protein coupled receptors (GPCRs), activation of AVPR1A and AVPR1B stimulate phospholipase C, while activation of AVPR2 stimulates adenylate cyclase. These three receptors for vasopressin have unique tissue distributions. AVPR1A are expressed in vascular smooth muscle cells, hepatocytes, platelets, brain cells, and uterus cells. AVPR1B are expressed in cells of the anterior pituitary and throughout the brain, especially in the pyramidal neurons of the hippocampal CA2 field. AVPR2 are expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, in fetal lung tissue and lung cancer, the last two being associated with alternative splicing. AVPR2 is also expressed in the liver where stimulation releases a variety of clotting factors into the bloodstream.
Balovaptan (RG7314)

Cat. No.: HY-109024

Balovaptan (RG7314) is a highly potent and selective brain-penetrant vasopressin 1a (hV1a) receptor antagonist, with $K_i$ values of 1 nM for human (hV1a) and mouse (mV1a) receptors, and is used for the research of autism.

Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Conivaptan hydrochloride

Cat. No.: HY-18347A

Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with $K_i$ values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Fuscoside (OPC-21268)

Cat. No.: HY-15009

Fuscoside (OPC-21268) is an orally effective, nonpeptide, receptor antagonist vasopressin V1 with an IC$_{50}$ of 0.4 μM.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lixivaptan (VPA-985; WAY-VPA 985)

Cat. No.: HY-14185

Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC$_{50}$ values of 1.2 and 2.3 nM for human and rat V2, respectively.

Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mozavaptan (OPC31260)

Cat. No.: HY-18346

Mozavaptan (OPC31260) is a orally effective, nonpeptide vasopressin V2 receptor antagonist with an IC$_{50}$ of 14 nM.

Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

RG7713 (RO5028442)

Cat. No.: HY-12981

RG7713 (RO5028442) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with $K_i$ of 1 nM (hV1a) and 39 nM (mV1a).

Purity: 99.49%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SRX246

Cat. No.: HY-105685

SRX246 is a potent, CNS-penetrant, highly selective, orally bioavailable vasopressin 1a (V1a) receptor antagonist (Ki=0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Terlipressin

Cat. No.: HY-12554

Terlipressin is a potent vasoconstrictor that acts via V1 receptors on arteriolar smooth muscle cells.

Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tolvaptan (OPC-41061)

Cat. No.: HY-17000

Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation.

Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg
<table>
<thead>
<tr>
<th>WAY-151932</th>
<th>(VNA-932; WAY-VNA 932)</th>
<th>Cat. No.: HY-19381</th>
</tr>
</thead>
<tbody>
<tr>
<td>WAY-151932 is a vasopressin V&lt;sub&gt;2&lt;/sub&gt;-receptor agonist with IC&lt;sub&gt;50&lt;/sub&gt; of 80.3 nM and 778 nM in human-V&lt;sub&gt;2&lt;/sub&gt; binding and V&lt;sub&gt;1a&lt;/sub&gt; binding assay.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purity:</td>
<td>&gt;98%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data:</td>
<td>No Development Reported</td>
<td></td>
</tr>
<tr>
<td>Size:</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>